Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters
    News

    Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters

    userBy userJanuary 11, 2025No Comments1 Min Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    (Reuters) – Gilead Sciences (NASDAQ:) said on Saturday that it entered into a partnership with Denmark’s LEO Pharma to develop programs to treat patients with inflammatory diseases.

    The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead.

    In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program.

    Targeting STAT6 has shown potential preclinically to treat a broad population of patients with inflammatory conditions such as atopic dermatitis, asthma, and COPD, the statement said.

    LEO Pharma may receive tiered royalties ranging from high single-digit to mid-teens on sales of topical STAT6 products.

    The transaction is expected to reduce Gilead’s GAAP and non-GAAP 2025 earnings per share by approximately $0.15 – $0.17.

    “By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions,” said Flavius Martin, executive vice president of research at Gilead Sciences.





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleI’m Nearing Retirement at 62. How Should I Arrange My Portfolio at This Point?
    Next Article Georgia Power restores power to 230,000+ customers following Winter Storm Cora By Investing.com
    user
    • Website

    Related Posts

    3 simple Warren Buffett wealth-building techniques you could use today

    June 7, 2025

    Here’s how to build a £10k+ second income from just 5 shares

    June 7, 2025

    These 5 shares could generate a £1,584 annual passive income from a £20k lump sum

    June 7, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d